Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

The tumour immune microenvironment is shaped by the crosstalk between cancer cells,
immune cells, fibroblasts, endothelial cells and other stromal components. Although the …

Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on
the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy …

Background In patients with early-stage triple-negative breast cancer, the phase 3
KEYNOTE-522 trial showed significant improvements in pathological complete response …

Background Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the
p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) …

Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …

Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant
improvement in invasive disease-free survival and distant relapse-free survival in hormone …

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …